Decisions:
Summary | Description |
|---|---|
Action Items:
Summary | Description | Responsible | Due Date |
|---|---|---|---|
| |||
Notes/ Discussion items:
Details:
Details of Transition Plan will be provided by email
Doc we will be working in can be found at https://docs.google.com/document/d/1gzA29bICFoiOs8hXjd4O7ZQGh1UzmuF_KfRSOHiXNdo/edit#. | |
Present-1/12/2021 | Each L2 Director & Deputy review your section of the doc and make any updates/changes, conferring with your L3 managers as needed. |
1/13-14/2021 | Review of full doc by all L2s. Please indicate when you have completed your review here: CEE/Kelly: ECSS/Bob & Phil: XCI/Dave: Ops/Greg: RAS/Dave: Pgo/Ron: |
1/15/2021 | John/Tim review plans from each area and provide feedback. |
1/18/2021 | Each L2 area makes changes based on John/Tim’s feedback |
1/19/2021 | John/Tim do final review to resolve any issues |
1/20/2021 | ER copyedit of document |
1/21/2021 | Leslie to format final doc in Word |
1/22/2021 | John’s final review and deliver to NSF. |
Spell out first instances of any acronyms in every major section of the report.
IPR14 will be followed closely by PY11 planning in mid-February
Scheduled will be emailed in mid January.
Risk review - n0 new risks, none retired
PCRs - there are 5 submitted and approved - using JIRA is a smooth
Recommendations - addressed 90% within 90 days, this is great!
Have 4 open recommendations - all assigned to Program Office
Staff Publications - 16 reported in RP2, please remind your area to enter this.
Wiki reminders: internal project tools are maintained on the wiki; also a link to User News page.
Appreciation to Leslie from the Evaluation Team